Completing data — refresh the page later to see the latest
444305-16-2CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)OGCTPUGMTPJIVNC-AYQWIQQISA-NSafety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
DescriptionMBP (85-99) peptide antagonist, or J5, is a 15 amino acid peptide fragment designed on the binding motif of MBP 85-99 (myelin basic protein 85-99) to HLA-DR2 (human leukocyte antigen-DR2), which competes with and inhibits the binding of MBP (85-99) to HLA-DR2 and IL-2. MBP 85-99 is the the immunodominant epitope of MBP and a major candidate autoantigen in multiple sclerosis (MS), making this peptide a useful tool for MS research. p>
444305-16-2